Last reviewed · How we verify
MANGAFODIPIR
MANGAFODIPIR is a paramagnetic contrast agent, a small molecule modality developed for use in magnetic resonance imaging (MRI). It was originally developed and is currently owned by a pharmaceutical company. MANGAFODIPIR is approved by the FDA for the indication of liver imaging, with an approval date of 1997. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As an off-patent drug, its commercial status is uncertain.
At a glance
| Generic name | MANGAFODIPIR |
|---|---|
| Drug class | Paramagnetic Contrast Agent |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Magnetic resonance imaging of liver
Common side effects
Key clinical trials
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy (PHASE1)
- Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients. (PHASE2)
- MEMRI and Kidney Disease
- Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity (PHASE2)
- Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
- Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
- Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus
- Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MANGAFODIPIR CI brief — competitive landscape report
- MANGAFODIPIR updates RSS · CI watch RSS